Renal Failure Clinical Trial
Official title:
The Prevalence and Severity of Nephrogenic Systemic Fibrosis in Patients Whom Underwent Imaging With Gadollinium(MRI/MRA) in University Hospital of Tehran Heart Center in 2003-2008
Recently there is increasing reports of NEPHROGENIIC SYSTEMIC FIBROSIS(NSF) in patients with
severe renal failure mainly in patients under dialysis in whom gadollinum is being used.
The investigators will evaluate the prevalence and severity of NSF in patients with
different degree of renal failure whom underwent imaging with Gadolinum.
NSF is a progressive and potentially fatal disease reported mainly in End Stage Renal
Disease (ESRD) patients in whom Gadolinume been used as contrast agent. Skin is the main
organ of involvement but other vital organs like myocard,lung,liver may also be
involved.Gadollinum is known as a safe contrast in renal disease patients in comparison with
conventional nephrotoxic radiocontrast agents,but with increasing reports of NSF with
Gadollinum the use of this agent in renal failure patients is under question.
We will retrospectively evaluate the occurrence of this complication in all patients with
different degree of renal failure whom underwent MRA or MRI with Gadollinum in Tehran Heart
Center since 2003 till now and we will describe the severity and distribution pattern of
lesions and the relation of this complication to the severity of renal failure.
;
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Screening
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02763410 -
Impact of the Composition of Packed Red Blood Cell Supernatant on Renal Dysfunction and Posttransfusion Immunomodulation
|
||
| Active, not recruiting |
NCT03183245 -
Comparison of the Human Acellular Vessel (HAV) With Fistulas as Conduits for Hemodialysis
|
Phase 3 | |
| Completed |
NCT04084301 -
Impact of Cardiopulmonary Bypass Flow on Renal Oxygenation, Blood Flow and Tubular Injury
|
N/A | |
| Completed |
NCT03292029 -
Pilot Medical Evaluation of the T50 Test
|
N/A | |
| Suspended |
NCT04589065 -
SCD for CRS in Congestive Heart Failure (CHF) (No Left Ventricular Assist Device)
|
N/A | |
| Completed |
NCT03806998 -
Effects of a Ketoacid Supplementation in Patients With Stage III to IV Renal Failure
|
Phase 3 | |
| Active, not recruiting |
NCT03672110 -
Slow and Low Start of a Tacrolimus Once Daily Immunosuppressive Regimen
|
Phase 3 | |
| Completed |
NCT02325726 -
RRI Compared With NephroCheckTM to Predict Acute Renal Failure After Cardiac Surgery.
|
N/A | |
| Completed |
NCT02116270 -
Accelerated Immunosenescence and Chronic Kidney Disease
|
N/A | |
| Completed |
NCT01859273 -
Adherence Enhancement for Renal Transplant Patients
|
N/A | |
| Completed |
NCT01388270 -
Effect of a Pre Heparin Coated Dialysis Filter on Coagulation During Hemodialysis
|
Phase 4 | |
| Completed |
NCT01187953 -
Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx
|
Phase 3 | |
| Completed |
NCT00966615 -
The Effect of Neutral Peritoneal Dialysis (PD) Solution With Minimal Glucose-Degradation-Product (GDP) on Fluid Status and Body Composition
|
Phase 4 | |
| Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A | |
| Completed |
NCT01008631 -
The Pharmacologic Profile of Sodium Thiosulfate in Renal Failure and Healthy Volunteers
|
N/A | |
| Completed |
NCT00765661 -
Pharmacokinetics of LCP-Tacro(TM) Once Daily And Prograf® Twice A Day in Adult De Novo Kidney Transplant Patients
|
Phase 2 | |
| Completed |
NCT00737672 -
GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis
|
Phase 3 | |
| Completed |
NCT00808691 -
Microcirculation and Oxidative Stress in Critical Ill Patients in Surgical Intensive Care Unit
|
N/A | |
| Recruiting |
NCT00470769 -
The Efficacy of Color-Doppler Ultrasonography to Assess the Renal Blood Flow With the Estimation of GFR
|
N/A | |
| Terminated |
NCT00338455 -
Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC
|
Phase 2 |